HBK Investments’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

HBK Investments’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-60,000	Closed	-$1.07M	–	1478
2018 Q3	$1.07M	Buy	+60,000	New	+$1.04M	0.01%	700

Other funds holding OPNT

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Brasada Capital Management Houston, Texas $545M AUM 18.58% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

HBK Investments's OPNT Position: Q4 2018 in Review

HBK Investments sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2018, closing a stake of 60,000 shares — an estimated $1.07M sold.

HBK Investments first reported a position in OPNT in Q3 2018 and held it in 1 quarter. The position peaked at $1.07M in Q3 2018. 23 funds tracked by Wall St. Rank hold OPNT as of Q4 2018.

HBK Investments reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
HBK Investments sold 60,000 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $1.07M.
HBK Investments first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
HBK Investments's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $1.07M in Q3 2018.
23 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on HBK Investments's 13F filing for Q4 2018, filed 14 Feb 2019.